Friday 6 November 2026 Export GKOS’s income statement to Excel — free account

Glaukos Corporation

GKOS Healthcare Medical Devices

Glaukos Corporation’s revenue for fiscal 2025 (year ended December 2025) was $507.4 million, up 32.3% from fiscal 2024.

Revenue: +58.0%
EPS: +110.7%
Free cash flow: +411.2%
Total debt: −2.25%

Quarter to September 2026, against a year earlier

Revenue growth 3 yrs

225.16 5.18 +2.35%

Follow GKOS

Alert me

Market cap: $13.0B
P/E: 0.0×
Fwd P/E: −803×
Dividend yield: —
F-score: 3/9
Altman Z: 15.20
Beneish M: −2.96
Dividend safety: n/a

Overview Business Profile Earnings & Analysis Segments Valuation Filings

Glaukos Corporation (GKOS) Price to free cash flow

Alert me on Price to free cash flow

As of 5 November 2026, Glaukos Corporation (GKOS) trades at a price to free cash flow of 360×. Over the past ten years it has ranged from 0.0× (September 2026) to 583× (September 2016); the current reading is higher than 98% of that period. That is above the Medical Devices industry median of 28.8× and above the Healthcare sector median of 21.1×.

Embed this chart

Code for your page

<iframe src="https://stockrow.com/embed/GKOS/price-to-free-cash-flow" width="100%" height="360" style="border:0" loading="lazy" title="Glaukos Corporation price to free cash flow, 10 years"></iframe>
<p style="font-size:12px">Source: <a href="https://stockrow.com/GKOS/metrics/price-to-free-cash-flow">Glaukos Corporation (GKOS) price to free cash flow — stockrow.com</a></p>

Period	Price to free cash flow	Change
FY2025	0.0×	—
FY2024	0.0×	—
FY2023	0.0×	—
FY2022	0.0×	—
FY2021	0.0×	—
FY2020	0.0×	—
FY2019	0.0×	—
FY2018	232×	392.98%
FY2017	47.1×	(74.43%)
FY2016	184×	—

Period	Price to free cash flow	Change
Sep 2026	269×	—
Jun 2026	0.0×	—
Mar 2026	0.0×	—
Dec 2025	0.0×	—
43 more quarters	Free account

Against its own ten years

Low 0.0× High 583×

Ten-year median 0.0×

Current reading's percentile 98

Company	Price to free cash flow
SNN Smith & Nephew SNATS, Inc. compare	7.1×
GMED Globus Medical, Inc. compare	14.5×
ZBH Zimmer Biomet Holdings, Inc. compare	18.2×
BIO Bio-Rad Laboratories, Inc. compare	30.0×
BIO.B Bio-Rad Laboratories, Inc. compare	30.7×
BRKR Bruker Corporation compare	32.9×
PODD Insulet Corporation compare	46.4×
PEN Penumbra, Inc. compare	63.1×
GKOS Glaukos Corporation	360×
Medical Devices industry median	28.8×
Healthcare sector median	21.1×
Market median	14.1×

What Price to free cash flow is

Price to Free Cash Flow Ratio shows how much investors pay for each dollar of cash a company generates after its capital spending.

Stock Price ÷ ((Operating Cash Flow (TTM) + Property, Plant, Equipment Change (Net) (TTM) + Intangible Assets Change (Net) (TTM)) ÷ (Shares (Basic, Weighted) (latest quarter)))

The full definition of Price to free cash flow →

Glaukos Corporation (GKOS) Price to free cash flow

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on GKOS

Price to free cash flow, daily

Annual newest first

Quarterly newest first

Against its own ten years

Price to free cash flow against peers

What Price to free cash flow is

More on GKOS

Stockrow Weekly